CORE B (Biostatistics) The Biostatistics Core (Core B) seeks to assure that all CRC investigators have access to state-of-the-art biostatistical support for all aspects of the design and conduct of their investigations.
Specific Aim 1 : To provide collaborative statistical support for investigations conducted by the members of the CLL Research Consortium (CRC) 1.1 To provide statistical support for the clinical research studies conducted by the CRC. 1.2 To provide statistical support for the laboratory studies conducted by the CRC, including both freestanding studies within the Projects and laboratory correlative studies embedded in the clinical trials. 1.3 To provide statistical support for murine studies conducted by the Projects.
Specific Aim 2 : To participate in the quality assurance and quality improvement processes for the CRC database 2.1 To participate in an ongoing process of quality improvement for the CRC database. 2.2 To advise on quality assurance as new types of data are incorporated into the CRC database.
Specific Aim 3; To participate in the scientific advisory committees of the CRC 3.1 To participate in teleconferences and meetings held by the Clinical Advisory Committee, the Scientific Advisory Committee, and the Data Safety and Monitoring Board. 3.2 To participate in the review of all sample requests submitted to the Tissue Core (Core C).
Specific Aim 4 : To provide a forum for statisticians working in CLL 4.1 To provide, through the distributed Biostatistics Core, a forum for statisticians working in CLL to improve their understanding of the disease and thereby provide even better statistical support to the Projects.
This Core facilitates research designed to translate the findings of basic science into information useful in the clinical arena for CLL patients. It provides a national resource consisting of a dataset of matched samples with corresponding pathological and clinical data. This interactive information on each CLL sample allows for a better understanding of the biology of CLL and improved prognosis and clinical trials for this leukemia.
|Barr, Paul M; Robak, Tadeusz; Owen, Carolyn et al. (2018) Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica 103:1502-1510|
|Kondo, K; Shaim, H; Thompson, P A et al. (2018) Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia 32:960-970|
|Hasan, Md Kamrul; Yu, Jian; Widhopf 2nd, George F et al. (2018) Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. Blood 132:170-178|
|Ten Hacken, Elisa; Valentin, Rebecca; Regis, Fara Faye D et al. (2018) Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight 3:|
|Gribben, John G (2018) How and when I do allogeneic transplant in CLL. Blood 132:31-39|
|Sivina, Mariela; Werner, Lillian; Rassenti, Laura et al. (2018) Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. Br J Haematol 180:597-600|
|Ott, Christopher J; Federation, Alexander J; Schwartz, Logan S et al. (2018) Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. Cancer Cell 34:982-995.e7|
|Balatti, Veronica; Tomasello, Luisa; Rassenti, Laura Z et al. (2018) miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients. Blood 132:2179-2182|
|Vangapandu, Hima V; Chen, Huiqin; Wierda, William G et al. (2018) Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells. Leuk Lymphoma 59:1427-1438|
|Yu, Jian; Chen, Yun; Chen, Liguang et al. (2018) Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma. Oncotarget 9:24731-24736|
Showing the most recent 10 out of 562 publications